Follow
C Day
C Day
Verified email at ncl.ac.uk
Title
Cited by
Cited by
Year
Steatohepatitis: a tale of two “hits”?
CP Day, OFW James
Gastroenterology 114 (4), 842-845, 1998
62501998
The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD
P Angulo, JM Hui, G Marchesini, E Bugianesi, J George, GC Farrell, ...
Hepatology 45 (4), 846-854, 2007
34882007
EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease
European Association for the Study of The Liver, ...
Obesity facts 9 (2), 65-90, 2016
25242016
Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease
G Targher, CP Day, E Bonora
New England Journal of Medicine 363 (14), 1341-1350, 2010
23472010
QT dispersion: an indication of arrhythmia risk in patients with long QT intervals.
CP Day, JM McComb, RW Campbell
Heart 63 (6), 342-344, 1990
21001990
Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis
QM Anstee, G Targher, CP Day
Nature reviews Gastroenterology & hepatology 10 (6), 330-344, 2013
19622013
Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
GP Aithal, CP Day, PJL Kesteven, AK Daly
The Lancet 353 (9154), 717-719, 1999
16971999
Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease
L Miele, V Valenza, G La Torre, M Montalto, G Cammarota, R Ricci, ...
Hepatology 49 (6), 1877-1887, 2009
16942009
Modeling nafld disease burden in china, france, germany, italy, japan, spain, united kingdom, and united states for the period 2016–2030
C Estes, QM Anstee, MT Arias-Loste, H Bantel, S Bellentani, J Caballeria, ...
Journal of hepatology 69 (4), 896-904, 2018
16052018
Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients
G Targher, L Bertolini, R Padovani, S Rodella, R Tessari, L Zenari, C Day, ...
Diabetes care 30 (5), 1212-1218, 2007
15282007
A position statement on NAFLD/NASH based on the EASL 2009 special conference
V Ratziu, S Bellentani, H Cortez-Pinto, C Day, G Marchesini
Journal of hepatology 53 (2), 372-384, 2010
14542010
Mortality after surgery in Europe: a 7 day cohort study
RM Pearse, RP Moreno, P Bauer, P Pelosi, P Metnitz, C Spies, B Vallet, ...
The Lancet 380 (9847), 1059-1065, 2012
14252012
The natural history of nonalcoholic fatty liver: a follow‐up study
MR Teli, OFW James, AD Burt, MK Bennett, CP Day
Hepatology 22 (6), 1714-1719, 1995
12721995
Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management
S McPherson, T Hardy, E Henderson, AD Burt, CP Day, QM Anstee
Journal of hepatology 62 (5), 1148-1155, 2015
12252015
Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis
AM Diehl, C Day
New England Journal of Medicine 377 (21), 2063-2072, 2017
12122017
HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin
AK Daly, PT Donaldson, P Bhatnagar, Y Shen, I Pe'er, A Floratos, MJ Daly, ...
Nature genetics 41 (7), 816-819, 2009
11732009
Non-alcoholic fatty liver disease: the mist gradually clears
NMW de Alwis, CP Day
Journal of hepatology 48, S104-S112, 2008
10582008
Simple non-invasive fibrosis scoring systems can reliably exclude advanced fibrosis in patients with non-alcoholic fatty liver disease
S McPherson, SF Stewart, E Henderson, AD Burt, CP Day
Gut 59 (9), 1265-1269, 2010
9812010
Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers
IN Guha, J Parkes, P Roderick, D Chattopadhyay, R Cross, S Harris, ...
Hepatology 47 (2), 455-460, 2008
9182008
Nonalcoholic fatty liver disease
EM Brunt, VWS Wong, V Nobili, CP Day, S Sookoian, JJ Maher, ...
Nature reviews Disease primers 1 (1), 1-22, 2015
8412015
The system can't perform the operation now. Try again later.
Articles 1–20